1Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia[ J]. Expert Opin lnvestig Drugs,2007,16(12) : 1955-1965.
2Tatemichi S, Tomiyama Y, Maruyama I, et al. Uroselectivity in male dogs of silodosin ( KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia [ J ]. Neurourol Urodyn,2006,25 (7) : 792-799,800-801.
3Matsubara Y, Kanazawa T, Kojima Y, et al. Pharmacokinetics and disposition of silodosin (KMD-3213) [ J]. Yakugaku Zasshi ,2006 ,126 :237-245.
4Kawabe K, Yoshida M, Homma Y,et al. Silodosin, a new alphalA-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase Ⅲ randomized, placebo-controlled, double-blind study in Japanese men [ J]. BJU Int,2006, 98(5) : 1019-1024.
5Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia[ J]. Int J Urol,2008,15 ( 11 ) :992-996.
9Safarinejad MR.Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older[J] ,Int Urol Nephrol,2008,40(4):921-931.
10Hayashi T,Sakai Y,Saito K,et al.A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia[J].Hinyokika Kiyo,2002,48(1):7-11.
